Microchip at Citi 2026 Global TMT Conference: recovery broadens

Microchip guided for September-quarter revenue growth of 40% year over year at the midpoint, supported by its strongest bookings in roughly four years, lean 25-day distributor inventory and broad-based strength across end markets. Gross margin is guided to 66.5%, though management said licensing revenue and distributor inventory repricing provide non-recurring support; it expects margins to remain in a 66%-67% range through fiscal 2027. Automotive revenue is up 29% year over year, aerospace and defense revenue has doubled to about $1 billion since 2022, and combined data-center revenue is expected to grow 69% this year, while PCIe Gen 6 and retimer design wins are not expected to contribute materially until 2027-28. Management will prioritize debt reduction, targeting net debt/EBITDA below 2.5x this quarter, leaving dividends flat and delaying buybacks.

Analysis

MCHP’s setup is fundamentally improving, but the equity is now exposed to a quality-of-growth debate rather than a simple recovery rerating. The near-term earnings upside is partly offset by non-recurring gross-margin support, while the company’s stated normalized margin ceiling limits the usual operating-leverage upside investors expect in a semiconductor upcycle. With the stock carrying a recovery/AI multiple, the critical Q2-Q3 catalyst is whether December guidance demonstrates that revenue acceleration converts into recurring operating-margin expansion after temporary items roll off.

The more differentiated upside sits in 2027-28, when PCIe Gen 6 programs can move from design wins to production. That creates an attractive but highly execution-dependent option on share recapture from established connectivity suppliers; TSM is an indirect beneficiary if MCHP’s advanced-node product ramps, though MCHP’s small scale means no material TSM earnings sensitivity. Conversely, external foundry and OSAT tightness is a hidden margin and service-risk: MCHP’s outsourced wafer exposure means AI-driven capacity scarcity could cap upside volume or require higher procurement costs, despite ample internal footprint capacity.

A&D is likely the highest-quality component of the mix because qualification cycles and reliability requirements reduce substitution risk, supporting a steadier earnings base if industrial/auto normalization slows under $100+ oil. The contrarian view is that broad bookings can still contain distributor-led demand brought forward by lengthening outsourced lead times; low channel inventory alone does not prove end-demand durability. The thesis is falsified by a December revenue guide below seasonal expectations, gross margin below 66%, or evidence that backlog growth is not converting to sell-through.

Key Decisions for Investors

• Do not chase MCHP on conference commentary. Build a 6-12 month long only on a post-earnings pullback or if the stock underperforms the SOX by 10%+, with a 15-20% upside target tied to sustained 66%+ gross margin and upward FY2027 EPS revisions; exit if December guidance signals a sub-66% margin reset.
• Prefer a relative-value long MCHP / short ADI over the next 3-6 months for investors seeking recovery exposure: MCHP has greater industrial/auto operating leverage and more room for multiple normalization, while ADI has a more mature AI-infrastructure narrative. Size modestly because ADI’s higher-quality margins can outperform if macro demand weakens.
• Treat PCIe Gen 6 as a 2027 catalyst, not a 2026 earnings driver. Set an alert for disclosed hyperscaler/ODM production awards, Gen 7 timing milestones, and initial 2027 revenue commitments; absence of incremental wins by mid-2027 would materially reduce the long-duration growth premium.
• Monitor outsourced foundry/OSAT lead times and MCHP gross-margin guidance each quarter. A further extension in external lead times without corresponding pricing recovery would favor a tactical reduction in MCHP exposure, as supply constraints would shift from evidence of demand to a revenue-conversion and margin risk.